<DOC>
	<DOCNO>NCT03018106</DOCNO>
	<brief_summary>Vulvovaginal atrophy ( VVA ) condition impact 60 % grow postmenopausal female population , common symptom dyspareunia . Vaginal estrogen common treatment VVA , marginally improve overall sexual function , many woman clinician avoid use risk exogenous estrogen use menopause . Ospemifene non-estrogen selective estrogen receptor modulator ( SERM ) FDA-approved treat dyspareunia relate VVA , show superb improvement overall sexual health . 104 woman randomize receive 12 week 60mg oral ospemifene , take daily , 12 week 0.5mg vaginal conjugate estrogen , place vaginally twice per week . The improvement sexual health VVA symptom severity compare group . This study help determine ospemifene well treatment medication conjugate estrogen .</brief_summary>
	<brief_title>Ospemifene vs. Conjugated Estrogens Treatment Postmenopausal Sexual Dysfunction</brief_title>
	<detailed_description>Female sexual dysfunction ( FSD ) affect 57 % postmenopausal woman . Vulvovaginal atrophy ( VVA ) condition impact 60 % grow postmenopausal female population , common symptom dyspareunia . Women FSD 3.84 time likely also VVA . Vaginal estrogen common treatment VVA , marginally improve overall sexual function , many woman clinician avoid use risk exogenous estrogen use menopause . Ospemifene non-estrogen selective estrogen receptor modulator ( SERM ) FDA-approved treat dyspareunia relate VVA , show superb improvement overall sexual health . This oral medication , take daily , improve vaginal health , demonstrate protective activity breast bone tissue . It also demonstrate carcinogenic activity endometrium liver . This study hop determine ospemifene superior conjugate estrogen improve sexual function vaginal atrophy symptom . 104 woman randomize receive 12 week 60mg oral ospemifene , take daily , 12 week 0.5mg vaginal conjugate estrogen , place vaginally twice per week . Each participant inform assigned medication , receive medication coupon help offset cost medication . Each medication FDA-approved long-term use least 52 week . For study , 12-week prescription medication send electronically pharmacy participant 's choice . The improvement sexual health VVA symptom severity compare group .</detailed_description>
	<mesh_term>Sexual Dysfunction , Physiological</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Interested resume continue sexual activity Greater 12 month since last menstrual cycle prior bilateral oophorectomy Dyspareunia vulvovaginal atrophy symptom Normal mammogram within 12 month prior entry study History suspicion breast carcinoma History hormonedependent tumor Genital bleed unknown cause Ongoing vaginal infection History cerebrovascular accident ( CVA ) , myocardial infarction ( MI ) heart disease Uncontrolled hypertension ( HTN ) 160/100 Serious disease chronic condition may prevent completion study Body Mass Index ( BMI ) 40 Hypercoagulable state , currently anticoagulant therapy Use exogenous sex hormone within three month study entry , study Pelvic surgery within last 12 month</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Female sexual disorder</keyword>
	<keyword>Aging</keyword>
	<keyword>Menopause</keyword>
	<keyword>Obstetrics/Gynecology</keyword>
	<keyword>Female urogenital disorder</keyword>
</DOC>